Albireo Stock Performance

ALBO
 Stock
  

USD 23.78  0.35  1.49%   

On a scale of 0 to 100, Albireo Pharma holds a performance score of 11. The firm shows a Beta (market volatility) of 1.1052, which signifies a somewhat significant risk relative to the market. Let's try to break down what Albireo's beta means in this case. Albireo Pharma returns are very sensitive to returns on the market. As the market goes up or down, Albireo Pharma is expected to follow. Although it is vital to follow Albireo Pharma historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy in foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Albireo Pharma, which you can use to evaluate the performance of the firm. Please makes use of Albireo Pharma value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall to make a quick decision on whether Albireo Pharma price patterns will revert.
  
Albireo Performance
11 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Albireo Pharma are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental drivers, Albireo Pharma disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more

Structure and Payout Changes

Last Split Factor
1:30
Dividend Date
2016-11-04
Last Split Date
2016-11-04

Albireo Price Channel

Begin Period Cash Flow251272000.00
Total Cashflows From Investing Activities102922000.00

Albireo Pharma Relative Risk vs. Return Landscape

If you would invest  1,632  in Albireo Pharma on September 6, 2022 and sell it today you would earn a total of  746.00  from holding Albireo Pharma or generate 45.71% return on investment over 90 days. Albireo Pharma is currently generating 0.7003% in daily expected returns and assumes 4.7687% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Albireo, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Albireo Pharma is expected to generate 0.38 times more return on investment than the market. However, the company is 2.62 times less risky than the market. It trades about 0.15 of its potential returns per unit of risk. The NYSE Composite is currently generating roughly -0.11 per unit of risk.

Albireo Pharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Albireo Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Albireo Pharma, and traders can use it to determine the average amount a Albireo Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1469

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsALBO
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 4.77
  actual daily
 
 41 %
of total potential
 
4141
Expected Return
 0.7
  actual daily
 
 13 %
of total potential
 
1313
Risk-Adjusted Return
 0.15
  actual daily
 
 11 %
of total potential
 
1111
Based on monthly moving average Albireo Pharma is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Albireo Pharma by adding it to a well-diversified portfolio.

About Albireo Pharma Performance

To evaluate Albireo Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Albireo Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Albireo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Albireo Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Albireo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-1.3 M-1.3 M
Return on Investment(65.60) (70.78) 
Return on Average Assets(11.58) (12.50) 
Return on Average Equity(19.07) (20.58) 
Return on Invested Capital 23.05  19.26 
Return on Sales(0.49) (0.53) 

Things to note about Albireo Pharma

Checking the ongoing alerts about Albireo Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Albireo Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Albireo Pharma Alerts

Equity Alerts and Improvement Suggestions

Albireo Pharma appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 40.58 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 39.22 M.
Albireo Pharma currently holds about 180.97 M in cash with (107.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.23.
Albireo Pharma has a frail financial position based on the latest SEC disclosures
Over 97.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Sale by Weisman Scott of 3851 shares of Albireo Pharma
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
CEO Directory
Screen CEOs from public companies around the world
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
492.3 M
Quarterly Revenue Growth YOY
1.68
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.